"Induction Chemotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.
| Descriptor ID |
D060828
|
| MeSH Number(s) |
E02.319.499 E02.860.500
|
| Concept/Terms |
Induction Chemotherapy- Induction Chemotherapy
- Chemotherapies, Induction
- Chemotherapy, Induction
- Induction Chemotherapies
|
Below are MeSH descriptors whose meaning is more general than "Induction Chemotherapy".
Below are MeSH descriptors whose meaning is more specific than "Induction Chemotherapy".
This graph shows the total number of publications written about "Induction Chemotherapy" by people in this website by year, and whether "Induction Chemotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 2 | 4 |
| 2017 | 2 | 0 | 2 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 2 | 4 |
| 2020 | 2 | 3 | 5 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 2 | 0 | 2 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Induction Chemotherapy" by people in Profiles.
-
Inclusion of Multi-Omic Biomarkers Improves Prediction Accuracy of Response, Relapse, and Overall Survival in Acute Myeloid Leukemia Patients Receiving High-Intensity Induction Chemotherapy. Cancer Med. 2026 Sep; 15(9):e72281.
-
Diagnostic BMI and Induction Therapy Weight Change Associated With Hepatotoxicity in Pediatric Patients With Acute Lymphoblastic Leukemia. Cancer Med. 2026 Sep; 15(9):e72218.
-
Toxicity from asparaginase during acute lymphoblastic leukemia induction: a report from the Children's Oncology Group. Blood Adv. 2026 07 28; 10(14):4923-4930.
-
An analysis of diagnostic metabolomic profiles associated with hepatotoxicity during childhood ALL induction therapy. Blood Adv. 2025 Nov 25; 9(22):5802-5810.
-
Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapy. Sci Rep. 2025 Oct 08; 15(1):35110.
-
Real-World Outcomes of Induction Chemotherapy With or Without Low-Dose Nivolumab for Stage III Non-Small Cell Lung Cancer Ineligible for Up-Front Local Therapy: A Propensity Score-Matched Analysis. JCO Glob Oncol. 2025 03; 11:e2400256.
-
Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood-Onset Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An ARChiVe Registry Cohort Study. Arthritis Care Res (Hoboken). 2025 Apr; 77(4):504-512.
-
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.
-
Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 12; 68(12):e29281.
-
Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. J Natl Cancer Inst. 2021 04 06; 113(4):408-417.